extract
Update: 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve (THV) Aortic Stenosis First in Human Study
Key Highlights:
1. The DurAVR™ Transcatheter Heart Valve (THV) First-in-Human Study met all performance endpoints with remarkable hemodynamic function sustained to 12 months.
2. DurAVR™ THV demonstrated an outstanding safety profile. All safety endpoints were met: No mortality (all causes), no disabling stroke, no life-threatening bleeding, and no myocardial infarction at 12 months.
3. These encouraging preliminary First-in-Human study results will be further validated in an FDA-approved Early Feasibility Study (EFS) in early 2023.
Ann: DurAVR First in Human Study 12 Month Results, page-2
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.95 |
Change
-0.050(0.50%) |
Mkt cap ! $208.6M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.80 | $63.23K | 6.443K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 344 | $9.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.97 | 52 | 1 |
View Market Depth
| Last trade - 14.17pm 11/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |